Salk Institute

Technologies Available for Licensing

Search Results - drug discovery

4 Results Sort By:
CNB-001- a novel synthetic pyrazole derivative of curcumin with neuroprotective, anti-oxidant and anti-inflammatory action
CNB-001 - a novel synthetic pyrazole derivative of curcumin with neuroprotective, anti-oxidant and anti-inflammatory action INVENTION: Investigators at the Salk Institute have designed, synthesized and optimized a novel pyrazole derivative of curcumin. CNB-001 displays much improved potency and metabolic stability over curcumin and is neuroprot...
Published: 4/10/2014   |   Inventor(s):  
Keywords(s): 5-lipoxygenase (5-LOX), Alzheimer's Disease, Amyloid-beta, Anti-oxidant, Asthma, Calcium Signaling, Drug Discovery, Neurodegenerative Disorders, Oxidative Stress, Parkinson's, Phosphatidylinositol 3'-kinase, Schubert, Stroke, tPA, Traumatic Brain Injury (TBI)
Category(s): Drug Discovery, Neurosciences and Ophthalmology
PPAR-delta Floxed Mice (Jackson Lab Strain 5897)
PPAR-delta Floxed Mice (Jackson Lab Strain 5897) INVENTION: Targeting of the nuclear prostaglandin receptor peroxisome proliferator-activated receptor-delta (PPAR-delta) by homologous recombination results in placental defects and frequent (>90%) midgestation lethality. Surviving PPAR-delta -/- mice exhibit a striking reduction in adiposit...
Published: 11/16/2013   |   Inventor(s):  
Keywords(s): Adipocyte Differentiation, Cardiovascular Disease, Coronary Artery Disease, Drug Discovery, Evans, Hyperlipidemia, Lipid Metabolism, Mouse Models, Obesity, PPAR-delta
Category(s): Research Reagents, Cardiovascular, Drug Discovery, Inflammation
PPAR-gamma-Null Embryonic Stem (ES) cells
PPAR-gamma-Null Embryonic Stem (ES) cells INVENTION: Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) is highly expressed in lipid-accumulating macrophages of the coronary artery. In light of this, the wide-spread clinical use of thiazolidinediones (TZDs) in the treatment of type II diabetes raises concerns about the role of PPAR-...
Published: 11/16/2013   |   Inventor(s):  
Keywords(s): Animal Models, Cardiovascular Disease, Cell Lines, Coronary Artery Disease, Diabetes, Drug Discovery, Evans, iPSC, Lipid Metabolism, Mouse Models, Obesity, PPAR-Gamma
Category(s): Research Reagents, Cardiovascular, Inflammation, Metabolic Disorders
Screening Platform for Cell Permeable Protein-Protein Interactions (PPI) Antagonists and Agonists
Screening Platform for Cell Permeable Protein-Protein Interactions (PPI) Antagonists and Agonists Assay captures all three PPI antagonist classes: Interface Binder, Conformation Trapper, Allosteric Inducer. INVENTION: Drs. Leo Li and Geoffery Wahl at the Salk Institute have developed a novel screening platform for the characterization of PPI...
Published: 11/15/2013   |   Inventor(s):  
Keywords(s): Drug Discovery, Drug Efficacy, High Throughput Screens, Mdm2, Mdm4, p53, Protein-Protein Interactions, Proteins, Ras, Wahl
Category(s): Drug Discovery
© 2017. All Rights Reserved. Powered by Inteum      

Get Involved
Join our online community
Facebook    Facebook
Twitter    Twitter
YouTube    YouTube
RSS    RSS
Contact
Salk Institute for Biological Studies
Street: 10010 North Torrey Pines Rd
City: La Jolla, CA 92037
Email: webrequest@salk.edu
Phone: 858.453.4100
Charity Navigator Rating
© Copyright 2012 Salk Institute for Biological Studies About Scientists & Research News & Media Events Support